Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system

Journal of Infection and Public Health

Volumn 7, Issue 1, 2014, Pages 50-53

  Ahmad, Farah ^a   Pogue, Jason M ^a,c   Marchaim, Dror ^c   Chopra, Teena ^b,c   Bheemreddy, Suchita ^c   Lee, Jiha ^c   Mudegowdra, Niveditha S ^b   Chaudhry, Aaisha ^c   Kaye, Keith S ^b,c  

^a SINAI GRACE HOSPITAL   (United States)

^b DETROIT MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial stewardship; Carbapenem; De escalation; Ertapenem; Streamlining

Indexed keywords

ERTAPENEM; IMIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC THERAPY; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CYSTIC FIBROSIS; ENTEROCOCCUS FAECALIS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; NOCARDIA; NOCARDIOSIS; OSTEOMYELITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTIMICROBIAL STEWARDSHIP; CARBAPENEM; DE-ESCALATION; ERTAPENEM; STREAMLINING;

ACADEMIC MEDICAL CENTERS; ACINETOBACTER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICHIGAN; MODELS, STATISTICAL; PSEUDOMONAS; RETROSPECTIVE STUDIES;

EID: 84892885977     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2013.09.004     Document Type: Article

References (10)

1. Paul M., Bishara J., Levcovich A., Chowers M., Goldberg E., Singer P., et al. Effectiveness and safety of colistin: a prospective comparative cohort study. J Antimicrob Chemother 2010, 65:1019-1027.
2. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009, 63:775-780.
3. Gallagher J.C., Rouse H.M. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008, 42:1188-1194.
4. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E. In vitro susceptibilities of aerobic and facultative anaerobic gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009, 34(December (6)):585-588.
5. Lima A.L., Oliveira P.R., Paula A.P., Dal-Paz K., Rossi F., Zumiotti A.V. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol 2009, 30:487-490.
6. Eagye K.J., Nicolau D.P. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol 2010, 31(5):485-490.
7. Goff D.A., Mangino J.E. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J Infect 2008, 57(August (2)):123-127.
8. Goldstein E.J., Citron D.M., Peraino V., Elgourt T., Meibohm A.R., Lu S. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009, 53:5122.
9. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
10. Reddy T., Chopra T., Marchaim D., Pogue J.M., Alangaden G., Salimnia H., et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother 2010, 54:2235-2238.